Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scilex Holding CoFRA:D8B0 -9.86%39 Days Payable is 1,916.30 as of Mar. 2026, which is 133% above its 10-year median of 823.10. GuruFocus rates FRA:D8B0 with a GF Score™ of 39/100 and a GF Value™ of €4.74 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 925 Drug Manufacturers companies, Scilex Holding Co ranks better than 97.73% on this metric.
The historical rank and industry rank for Scilex Holding Co's Days Payable or its related term are showing as below:
FRA:D8B0'
s Days Payable Range Over the Past 10 Years
Min: 215.24 Med: 823.1 Max: 2391.42
Current: 1985.66
During the past 7 years, Scilex Holding Co's highest Days Payable was 2391.42. The lowest was 215.24. And the median was 823.10.
FRA:D8B0's Days Payable is ranked better than 97.73% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs FRA:D8B0: 1985.66
Scilex Holding Co's Days Payable
declined
from Mar. 2025 (3,676.18) to Mar. 2026 (1,916.30).
It may suggest that Scilex Holding Coaccelerated paying its suppliers.
Scilex Holding Co Days Payable Related Terms
Scilex Holding Co Days Payable Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:D8B0 vs MIRA, NSRX, MDCX: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Scilex Holding Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (FRA:D8B0) has a Days Payable of 1,916.30 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scilex Holding Co and its competitors. This is 133% above median its historical median of 823.10. Over the past decade, Scilex Holding Co's Days Payable has ranged from 215.24 to 2,391.42. According to the industry distribution chart, Scilex Holding Co ranks #21 out of 925 companies in the Drug Manufacturers industry, placing it in the top 2.3%.
Is Scilex Holding Co's Days Payable too high?
Scilex Holding Co's current Days Payable of 1,916.30 is 133% above median its 10-year median of 823.10. Over the past 10 years, this metric has ranged from a low of 215.24 to a high of 2,391.42. The Drug Manufacturers industry median Days Payable is 90.38. Scilex Holding Co's value of 1,916.30 is 2020.3% above this industry median. Based on the distribution chart, Scilex Holding Co ranks #21 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Scilex Holding Co has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Days Payable compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #21 out of 925 companies for Days Payable. This places Scilex Holding Co in the top 2% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Scilex Holding Co's value of 1,916.30 is 2020.3% above this benchmark. Historically, Scilex Holding Co's own Days Payable has ranged from 215.24 to 2,391.42 over the past decade. While the company's 10-year median is 823.10 vs. the industry median of 90.38, Scilex Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scilex Holding Co's current Days Payable of 1,916.30 is 2020.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scilex Holding Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current Days Payable is 1,916.30, which is 133% above median its own 10-year median of 823.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (FRA:D8B0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.74, compared to a current price of €6.40 — trading 35% above its estimated fair value. The current Days Payable is 1,916.30, which is 133% above median its 10-year median of 823.10 and 2020.3% above the Drug Manufacturers industry median of 90.38. Scilex Holding Co's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Scilex Holding Co (FRA:D8B0), the current Days Payable is 1,916.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (FRA:D8B0) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued.
The current stock price of €6.40 is trading 35% above its estimated GF Value™ of €4.74.
GuruFocus considers Scilex Holding Co to be Significantly Overvalued.
Key valuation signals for FRA:D8B0:
Days Payable: 1,916.30 (133% above median its 10-year median of 823.10)
GF Value™: €4.74 vs. price of €6.40 (35% above fair value)
Industry Position: 2020.3% above the Drug Manufacturers median (#21 of 925)
No single metric tells the full story. See the FRA:D8B0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
39GF Score
Get the complete analysis for FRA:D8B0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D8B0 has been successfully added to your 
